NCT04219124View on ClinicalTrials.gov

The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

January 8, 2020

Study Completion Date

January 8, 2020

Conditions
Type 2 Diabetes
Interventions
DRUG

IMP oral tablet

Dapagliflozin 10 MG

DRUG

Placebo oral tablet

Matching placebo tablets

Trial Locations (1)

GU2 7XX

CEDAR, Royal Surrey County Hospital, Guildford

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Royal Surrey County Hospital NHS Foundation Trust

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

University of Leicester

OTHER